Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4690678 | PMC |
| http://dx.doi.org/10.4212/cjhp.v68i6.1507 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Asparaginase therapy in patients with acute lymphoblastic leukemia: expert opinion on use and toxicity management.
Leuk Lymphoma
April 2023
Department of Pharmacy, Cancer and Blood Disorders Center, Seattle Children's Hospital, Seattle, WA, USA.
The addition of asparaginase to acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) treatment regimens provides significant patient benefits. Asparaginase therapies vary in origin ( or -derived) and preparation (native or pegylated), conferring distinct pharmacokinetic and immunogenic profiles. Clinical hypersensitivity reactions (HSRs) are commonly reported in patients and range from localized erythema to systemic anaphylaxis.
View Article and Find Full Text PDFIV Administration of Erwinia-Derived Asparaginase in Pediatric Patients with Acute Lymphoblastic Leukemia: Single-Centre Case Series.
Can J Hosp Pharm
December 2015
MD, FRCPC, is a Physician with Paediatric Haematology/ Oncology, Children's Hospital, London Health Sciences Centre, and an Assistant Professor with the Department of Paediatrics, University of Western Ontario, London, Ontario.
A retrospective study was undertaken comparing the frequency and severity of anaphylactic reactions to E. coli-derived and Erwinia-derived asparaginase given intravenously on a weekly dosage schedule. Both drugs were found to produce life-threatening hypersensivity reactions with the chance of reaction per dose administered being almost identical--8% for each dose administered.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!